Sanofi (NASDAQ: SNY) Stock Competitors & Peer Comparison
See SNY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SNY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNY | $42.48 | -1.53% | 102B | 9.25 | $4.59 | +5.69% |
| LLY | $1,152.22 | -0.02% | 1.1T | 36.61 | $31.49 | +0.58% |
| JNJ | $269.99 | -0.09% | 650.6B | 25.16 | $10.73 | +1.94% |
| ABBV | $263.78 | -0.09% | 466.1B | 25.89 | $10.19 | +2.58% |
| MRK | $146.76 | -0.27% | 362.5B | 45.72 | $3.21 | +2.32% |
| NVS | $140.37 | -0.39% | 266.8B | 16.15 | $8.69 | +3.38% |
| AZN | $166.08 | -0.04% | 257.5B | 17.93 | $9.26 | +1.94% |
| AMGN | $385.65 | +2.47% | 205B | 16.98 | $22.37 | +2.58% |
| NVO | $43.24 | +0.12% | 192B | 10.76 | $4.02 | +4.13% |
| GILD | $150.11 | -0.52% | 186.4B | -384.90 | -$0.39 | +2.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
SNY vs LLY Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while LLY trades at $1,152.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas LLY's P/E ratio is 36.61. In terms of profitability, SNY's ROE is +0.06%, compared to LLY's ROE of +0.93%. Regarding short-term risk, SNY is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for SNY.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
SNY vs JNJ Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while JNJ trades at $269.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas JNJ's P/E ratio is 25.16. In terms of profitability, SNY's ROE is +0.06%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, SNY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for SNY.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
SNY vs ABBV Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while ABBV trades at $263.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas ABBV's P/E ratio is 25.89. In terms of profitability, SNY's ROE is +0.06%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, SNY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for SNY.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
SNY vs MRK Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while MRK trades at $146.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas MRK's P/E ratio is 45.72. In terms of profitability, SNY's ROE is +0.06%, compared to MRK's ROE of +0.07%. Regarding short-term risk, SNY is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for SNY.Check MRK's competition here
Novartis AG (NYSE: NVS)
SNY vs NVS Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while NVS trades at $140.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas NVS's P/E ratio is 16.15. In terms of profitability, SNY's ROE is +0.06%, compared to NVS's ROE of +0.30%. Regarding short-term risk, SNY is less volatile compared to NVS. This indicates lower risk in terms of short-term price fluctuations for SNY.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
SNY vs AZN Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while AZN trades at $166.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas AZN's P/E ratio is 17.93. In terms of profitability, SNY's ROE is +0.06%, compared to AZN's ROE of +0.22%. Regarding short-term risk, SNY is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
SNY vs AMGN Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while AMGN trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas AMGN's P/E ratio is 16.98. In terms of profitability, SNY's ROE is +0.06%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, SNY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
SNY vs NVO Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while NVO trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas NVO's P/E ratio is 10.76. In terms of profitability, SNY's ROE is +0.06%, compared to NVO's ROE of +0.59%. Regarding short-term risk, SNY is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for SNY.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
SNY vs GILD Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while GILD trades at $150.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas GILD's P/E ratio is -384.90. In terms of profitability, SNY's ROE is +0.06%, compared to GILD's ROE of -0.16%. Regarding short-term risk, SNY is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
SNY vs PFE Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while PFE trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas PFE's P/E ratio is 9.05. In terms of profitability, SNY's ROE is +0.06%, compared to PFE's ROE of +0.05%. Regarding short-term risk, SNY is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for SNY.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
SNY vs BMY Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while BMY trades at $63.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas BMY's P/E ratio is 10.63. In terms of profitability, SNY's ROE is +0.06%, compared to BMY's ROE of +0.47%. Regarding short-term risk, SNY is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BMY's competition here
GSK plc (NYSE: GSK)
SNY vs GSK Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while GSK trades at $50.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas GSK's P/E ratio is 10.85. In terms of profitability, SNY's ROE is +0.06%, compared to GSK's ROE of +0.24%. Regarding short-term risk, SNY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
SNY vs BIIB Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while BIIB trades at $215.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas BIIB's P/E ratio is 13.60. In terms of profitability, SNY's ROE is +0.06%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, SNY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
SNY vs HZNP Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SNY's ROE is +0.06%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SNY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for SNY.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
SNY vs GRFS Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while GRFS trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas GRFS's P/E ratio is 8.40. In terms of profitability, SNY's ROE is +0.06%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, SNY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
SNY vs OGN Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while OGN trades at $13.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas OGN's P/E ratio is 4.09. In terms of profitability, SNY's ROE is +0.06%, compared to OGN's ROE of +0.23%. Regarding short-term risk, SNY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for SNY.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
SNY vs AMRN Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while AMRN trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas AMRN's P/E ratio is -138.70. In terms of profitability, SNY's ROE is +0.06%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, SNY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
SNY vs SCLX Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while SCLX trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas SCLX's P/E ratio is -0.13. In terms of profitability, SNY's ROE is +0.06%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, SNY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for SNY.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
SNY vs MIRA Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while MIRA trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas MIRA's P/E ratio is -0.56. In terms of profitability, SNY's ROE is +0.06%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, SNY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for SNY.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
SNY vs SCLXW Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas SCLXW's P/E ratio is N/A. In terms of profitability, SNY's ROE is +0.06%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, SNY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for SNY.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
SNY vs BDSIW Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, SNY's ROE is +0.06%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SNY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
SNY vs CRXT Comparison September 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 102B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SNY is priced at $42.48 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 9.25, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SNY's ROE is +0.06%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SNY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for SNY.Check CRXT's competition here